AtriCure, Inc. (ATRC) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Atricure, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.656 participants are in listen-only mode. We will be facilitating a question-and-answer session 00:00:05.656 -- 00:00:09.259 following the prepared remarks by HHR's management. 00:00:09.259 -- 00:00:13.763 I would now like to turn the call over to Marisa Beisch from the Gilmartin Group for 00:00:13.763 -- 00:00:16.624 a few introductory comments. 00:00:18.267 -- 00:00:23.172 Thank you. By now, you should have received a copy of the earnings press release. 00:00:23.172 -- 00:00:27.574 If you have not received a copy, please call 513-644-7000. 00:00:28.448 -- 00:00:32.053 to have one emailed to you. 00:00:32.053 -- 00:00:36.398 Before we begin today, let me remind you that the company's remarks include forward-looking 00:00:36.398 -- 00:00:42.305 statements. Forward-looking statements are subject to numerous risks and uncertainties, 00:00:42.305 -- 00:00:47.212 many of which are beyond HRCUR's control, including risks and uncertainties described 00:00:47.212 -- 00:00:51.156 from time to time in HRCUR's SEC filings. 00:00:51.156 -- 00:00:57.068 These statements include, but are not limited to, financial expectations and guidance, 00:00:57.068 -- 00:01:01.974 expectations regarding the potential market opportunity for Atricure's franchises and 00:01:01.974 -- 00:01:03.756 growth initiatives, 00:01:03.756 -- 00:01:08.801 future product approvals and clearances, competition, reimbursement, 00:01:08.801 -- 00:01:11.584 and clinical trial outcomes. 00:01:11.584 -- 00:01:14.708 Atricure's results may differ materially from those projected. 00:01:14.708 -- 00:01:16.169 Atricure 00:01:16.169 -- 00:01:21.836 undertakes no obligation to publicly update any forward-looking statement. 00:01:21.836 -- 00:01:25.030 Additionally, we refer to non-GAAP fi...